Adar1 Capital Management, LLC Arcutis Biotherapeutics, Inc. Call Options Transaction History
Adar1 Capital Management, LLC
- $530 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ARQT
# of Institutions
193Shares Held
128MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.6MShares$98.6 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$85.2 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$83.6 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$74.9 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$73.5 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $513M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...